The landscape of intrinsic and evolved fluoroquinolone resistance in *Acinetobacter baumannii* includes suppression of drug-induced prophage replication.

Running Head: Antibiotic resistance modulation of prophage induction

Edward Geisinger, a, c Germán Vargas-Cuebas, a* Nadav J. Mortman, a Sapna Syal, a Elizabeth L. Wainwright, c David Lazinski, a Stephen Wood, b Zeyu Zhu, b Jon Anthony, b Tim van Opijnen, b Ralph R. Isberg a#

a Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA

b Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA

c Department of Biology, Northeastern University, Boston, Massachusetts, USA

#To whom correspondence should be addressed (ralph.isberg@tufts.edu)

*Present address: Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA

Abstract word count: 396 (Abstract section: 248; Importance section: 148)

Text word count: 5,979
Abstract

The emergence of fluoroquinolone resistance in nosocomial pathogens has restricted the clinical efficacy of this antibiotic class. In *Acinetobacter baumannii*, the majority of clinical isolates now show high-level resistance due to mutations in *gyrA* (DNA gyrase) and *parC* (Topo IV). To investigate the molecular basis for fluoroquinolone resistance, an exhaustive mutation analysis was performed in both drug sensitive and resistant strains to identify loci that alter the sensitivity of the organism to ciprofloxacin. To this end, parallel fitness tests of over 60,000 unique insertion mutations were performed in strains with various alleles in genes encoding the drug targets. The spectrum of mutations that altered drug sensitivity was found to be similar in the drug sensitive and double mutant *gyrAparC* background having resistance alleles in both genes. In contrast, introduction of a single *gyrA* resistance allele, resulting in preferential poisoning of Topo IV by ciprofloxacin, led to extreme alterations in the insertion mutation fitness landscape. The distinguishing feature of preferential Topo IV poisoning was induction of DNA synthesis in the region of two endogenous prophages, which appeared to occur *in situ*. Induction of the selective DNA synthesis in the *gyrA* background was also linked to enhanced activation of SOS response and heightened transcription of prophage genes relative to that observed in either the WT or *gyrAparC* double mutants. Therefore, the accumulation of mutations that result in the stepwise evolution of high ciprofloxacin resistance is tightly connected to suppression of hyperactivation of the SOS response and endogenous prophage DNA synthesis.
**Importance**

Fluoroquinolones have been extremely successful antibiotics. Their clinical efficacy derives from the ability to target multiple bacterial enzymes critical to DNA replication, the topoisomerases DNA gyrase and Topo IV. Unfortunately, mutations lowering drug affinity for both enzymes are now widespread, rendering these drugs ineffective for many pathogens. To undermine this form of resistance, we sought to understand how bacteria with target alterations differentially cope with fluoroquinolone exposures. We studied this problem in the nosocomial pathogen *A. baumannii*, which causes resistant, life-threatening infections. Employing genome-wide approaches, we uncovered numerous pathways that could be exploited to lower fluoroquinolone resistance independently of target alteration. Remarkably, fluoroquinolone targeting of Topo IV in specific mutants caused dramatic prophage hyperinduction, a response that was muted in strains with DNA gyrase as the primary target. This work demonstrates that resistance evolution via target modification can profoundly modulate the antibiotic stress response, revealing potential resistance-associated liabilities.

**Introduction**

*Acinetobacter baumannii* is a frequent cause of multidrug resistant infections in hospitals and has been labeled a pathogen of critical priority for new drug development (1). This pathogen class has rapidly evolved a broad array of drug resistance mechanisms, limiting the usefulness of many widely-used antibiotics. A prime example is the fluoroquinolone class of antibiotics. These drugs are widely used to treat infections caused by a range of Gram-negative and Gram-positive bacteria, but they have been rendered obsolete against most *A. baumannii* isolates due to extremely high frequencies of resistance (2-4). Understanding how *A. baumannii* and related
bacteria withstand treatment with fluoroquinolone antibiotics has the potential to lead to strategies to reverse or bypass resistance.

Fluoroquinolones inhibit DNA replication in bacteria by targeting two enzymes essential for DNA synthesis, the type II topoisomerases DNA gyrase (*gyrAB* genes) and topoisomerase IV (Topo IV, *parCE*). These enzymes modulate DNA topology to maintain negative DNA supercoiling (DNA gyrase) or decatenate newly replicated DNA (Topo IV), and in so doing, break and religate DNA. Binding of fluoroquinolones to these enzymes traps them in an intermediate state that is bound to cleaved DNA, resulting in double-strand DNA breaks, blocked replication fork progression and, at high drug concentrations, cell death (5).

Acquired resistance to fluoroquinolones commonly arises through stepwise mutations that disrupt the ability of the drug to bind its preferred target enzymes. In Gram-negative bacteria including *A. baumannii*, these mutations typically arise first in *gyrA*, encoding the GyrA subunit of DNA gyrase which is the more sensitive of the two enzyme targets (6). In the presence of resistant GyrA, the less sensitive Topo IV (encoded by *parC*) becomes the target and the site of second-step resistance mutations. In addition to target site alterations, acquisition of mutations that upregulate drug efflux pumps or accessory genes that allow drug modification enable bacteria to develop fluoroquinolone resistance (7). A large fraction of *A. baumannii* isolates harbor target-site mutations in *gyrA* and *parC* (8, 9) and mutations causing overproduction of one or more RND-class efflux systems that act on fluoroquinolone drugs (AdeABC, AdeFGH, AdeIJK (10-12)).

Acquired resistance mechanisms generally act in combination with intrinsic resistance strategies in a cumulative manner to raise the amount of fluoroquinolone antibiotic required to block bacterial growth. Regulated production of native efflux pumps contributes to intrinsic
fluoroquinolone resistance in many bacteria (13). Of the RND systems in A. baumannii, native levels of AdeIJK in wild-type (WT) strains lacking acquired mutations have been shown to provide intrinsic resistance to fluoroquinolones (12). Whether regulated production of other efflux systems provides intrinsic fluoroquinolone resistance is less clear.

Another major strategy for intrinsic fluoroquinolone resistance is activation of DNA damage repair pathways (14). DNA lesions caused by fluoroquinolone intoxication are processed to single-stranded DNA and subsequently induce the SOS repair response, resulting in de-repression of many genes involved in DNA recombination and repair (15). Knockout mutations in a variety of DNA repair genes result in increased fluoroquinolone susceptibility in several species (14-24). In certain cases, the SOS response also induces mobile genetic elements that carry antibiotic resistance or toxin genes, potentially influencing the spread of resistance or virulence traits (25). The A. baumannii SOS repair response is non-canonical, lacking clear orthologs of many major players in other systems (26) and is characterized by a phenotypically variable response within cell populations (27). Inactivation of RecA, a central protein mediating DNA recombinational repair and SOS induction, or the RecBCD Exonuclease V complex responsible for double-strand break repair, greatly raises fluoroquinolone sensitivity in A. baumannii (28, 29). The role of the SOS response and other DNA repair systems, however, in the development of antibiotic resistance in this organism is largely unknown.

In this study, we present the results of a comprehensive screen for determinants of intrinsic resistance to the fluoroquinolone antibiotic ciprofloxacin in A. baumannii. We hypothesized that the ciprofloxacin resistome varies depending on the drug target (DNA gyrase or Topo IV) that is preferentially poisoned, which is determined by possession of WT or resistant versions of the enzymes. We therefore performed parallel screens with isogenic A. baumannii
strains containing sensitive or resistant gyrA and parC alleles to uncover the influence of target selectivity on the intrinsic resistance landscape. This analysis led to the surprising discovery that endogenous prophage activation by fluoroquinolones shows dramatic dependence on the availability of a sensitive parC allele.

**Results**

**Identification of *Acinetobacter baumannii* loci that confer altered sensitivity to ciprofloxacin.** As part of a largescale effort to characterize the molecular nature of intrinsic resistance of *Acinetobacter baumannii* to antimicrobials, we identified the entire spectrum of insertion mutations that cause altered sensitivity to the fluoroquinolone antibiotic ciprofloxacin during growth in bacteriological culture. A number of studies have demonstrated that mutations that cause antibiotic hypersensitization in strain backgrounds lacking demonstrable resistance loci exhibit these effects independently of whether there are target site resistance mutations or antibiotic-inactivating enzymes present in the strains being interrogated (20, 30). We wanted to test this model by first identifying loci that confer intrinsic resistance in a strain background having intact drug targets, and then comparing them with intrinsic resistance loci identified in strains having drug target mutations in DNA gyrase or Topo IV. For this work, we will refer to lesions resulting in lowered resistance to the antibiotic as ciprofloxacin-hypersensitizing mutations in each strain background, and the genes harboring these mutations as loci of hypersensitization.

To identify ciprofloxacin hypersensitization loci, ciprofloxacin concentrations below the minimal inhibitory concentration (MIC) (Table 1) were identified that resulted in growth rates of
A. baumannii ATCC17978 in rich broth that were between 60-80% of that observed without antibiotics (Fig. 1A). Three of these concentrations were chosen for further analysis (0.05, 0.075 and 0.09-0.10 μg/ml) to determine the relative fitness of insertion mutations when subjected to each of the antibiotic stress conditions. Multiple independent Tn10 insertion pools (7 pools for 0.05 μg/ml, and 11 pools for 0.075 and 0.09-0.10 μg/ml ciprofloxacin) having between 6,000 and 18,000 individual insertions (60,000 separate sites in all) were grown in broth in the presence or absence of ciprofloxacin for approximately 8 generations. DNA samples taken from the initial time point prior to growth (t1) and the final timepoint after 8 generations growth (t2) were prepared from each of the pools. The insertion sites were then amplified preferentially and subjected to high density sequencing, followed by determining the relative fitness of each insertion mutant based on density of reads (Materials and Methods; Data Set S1). Using accepted strategies, the fitness of each insertion mutant strain was calculated relative to the entire pool (31). To standardized results across experiments, fitness values were normalized to insertions found in 18 neutral sites located in pseudogenes or endogenous transposon-related genes throughout the genome ("neutral" mutants), to allow an accurate quantitation of the representation of mutants relative to control insertions predicted to have no effect on growth (32). The normalized data from the individual insertion mutations were aggregated for each gene to calculate a mean fitness level for the entire spectrum of mutations found within a particular gene. The complete datasets were then displayed on an individual gene level as the growth rate changes for mutations relative to the growth rate of the entire pool (Fig. 1B). Candidate mutants were identified that showed lower (hypersensitizing loci) or higher fitness levels based on the criteria that the False Discovery Rate (FDR) q value was <0.05, a change in
fitness ($W_{\text{diff}}$) was >10%, and fitness value was derived from at least 3 independent insertion mutants ((33); Materials and Methods).

Small increases in the dose of ciprofloxacin greatly increased the spectrum of ciprofloxacin hypersensitivity loci (Fig. 1B; black). At a dose causing approximately 20% growth inhibition, mutations in only 10 genes passed the criteria for lower fitness relative to the rest of the pool in the presence of the drug. These included insertions in: two genes involved in double strand break repair ($\text{recB}$ and $\text{ruvA}$, encoding subunits of exonuclease V and the Holiday junction helicase); the major egress pump which is often found overproduced in clinical strains having high level fluoroquinolone resistance ($\text{adeIJK}$); and $\text{ctpA}$, a periplasmic protease shown to be a target of mutations that augment $\beta$-lactam resistance in strains lacking the $\text{bfmRS}$ global regulatory system (34) (Data Set S1). Increasing the drug dose had two effects on expanding the spectrum of hypersensitivity loci. First, although the number of hypersensitivity loci that contribute to the enzymology of DNA repair increased from 2 members to 20 in the high dose regimen, this expansion largely involved hitting additional subunits of the same complexes or backup systems of the enzymes identified in the low dose regimen ($\text{recBCD}$, $\text{sbcCD}$, $\text{ruvABC}$) (Data Set S1). This emphasizes the importance of protecting against double strand breaks caused by fluoroquinolone-poisoned DNA gyrase (35). Secondly, increasing dose resulted in hypersensitivity loci in cell envelope integrity proteins, additional protein-processing enzymes, and a MATE class proton-driven efflux pump ($\text{abeM}$) shown to export ciprofloxacin and other antibiotic compounds when cloned in $\text{E. coli}$ (36) (Data Set S1; Fig. 1C). Interestingly, increasing the drug dose did not implicate the two other major RND efflux systems in protecting from ciprofloxacin stress even though they are known to provide low-level resistance after overproduction (12). This may be explained by the fact that the $\text{adeIJK}$ system is the only RND
egress pump known to have a high basal level of expression in WT strains lacking acquired resistance mutations, while the inducing signals for the other systems have not been identified (12). Strikingly, at the higher drug doses, mutations in \( adeN \), which encodes the negative regulator of \( adeIJK \), increased the fitness of \( A. baumannii \) relative to the rest of the pool (Data Set S1). These data argue strongly that the primary efflux pumps involved in intrinsic protection from fluoroquinolone stress are AdeIJK and AbeM.

In addition to hypersensitivity loci, mutations were identified at the highest drug dose that resulted in increased fitness relative to the insertion pool (Fig. 1B and C, Data Set S1). The mutations that most frequently increased fitness targeted nonessential components of the protein translation machinery, particularly enzymes that post-translationally modify tRNA, rRNA and assembly of ribosomal protein complexes. That disruption of this circuit is tightly associated with increased drug resistance is consistent with studies showing that a spectrum of antibiotic resistant isolates in different species evolve mutations causing slowed translation rate (37, 38). The results are also consistent with a study demonstrating that lowering ribosomal synthesis increases resistance to ciprofloxacin by restoring an optimal balance between protein and DNA synthesis levels during DNA stress (39)). Most notable among the insertions identified were those in \( gidA \), which is part of a complex involved in 5-methylaminomethyl-2-thiouridine (\( \text{mm}^5\text{s}^2\text{U}_{34} \)) modification of tRNAs (Data Set S1; (40)). We have previously identified this gene as an additional target of mutations bypassing drug hypersensitivity resulting from loss of \( bfmRS \) (34), indicating the tight connection between mutations in this gene and drug resistance.

**Deletion mutants have drug sensitivities predicted by Tn-seq.** Targeted deletion or null mutations were isolated in nonessential genes predicted to have altered drug sensitivity in the presence of ciprofloxacin. The mutations were chosen based on their fitness in the Tn-seq
analysis, the magnitude of the effects predicted, and differing functional categories (Fig. 1C). For instance, mutations in the egress pump-encoding adeIJK showed extremely poor fitness and were rarely recovered after growth in ciprofloxacin (Fig. 2A). Similarly, the insertions in ctpA showed very low fitness. In contrast, although ciprofloxacin treatment lowered fitness for mutants lacking the penicillin binding protein PBP1A, these mutations clearly had weaker effects in the Tn-seq analysis. When this set of targeted mutants was analyzed further, loss of adeIJK, recN, ctpA and pbp1A all resulted in heightened drug sensitivity (Fig. 2B). In contrast, deletion of gidA-encoded tRNA modification enzyme resulted in enhanced fitness in the presence of ciprofloxacin, with increased yields in broth cultures exposed to 0.15 µg/ml of antibiotic (Fig. 2B).

**Identification of loci that result in altered ciprofloxacin sensitivity in A. baumannii**

target site mutants. A majority of the current clinical isolates of A. baumannii are resistant to fluoroquinolones, and these isolates commonly have the gyrA(S81L) and parC(S84L) target site mutations that lower the affinity for these antibiotics (41). To determine the spectrum of insertions that cause altered sensitivity to ciprofloxacin in strains having resistance alleles, gyrA(S81L) (hereafter referred to as gyrAR) and gyrA(S81L) parC(S84L) (referred to as gyrAR parCR) mutants were generated, and each strain was subjected to Tn10 mutagenesis. Pools totaling more than 70,000 insertion mutations were constructed in each background. Insertion pools were challenged with ciprofloxacin, using drug concentrations below the MIC (Table 1) that resulted in 30-40% growth inhibition for each strain (1.1µg/ml for gyrAR; 13-14 µg/ml for gyrAR parCR double mutant; Fig. 3A). The spectrum of insertions that resulted in hypersensitivity to ciprofloxacin in the gyrAR parCR double mutant strain backgrounds was very similar to the WT (Fig. 3C,D). In fact, almost every ciprofloxacin hypersensitive locus in the
double mutant background was identified previously in the WT (green circles, Fig. 3C; Data Sets S1 and S3). In addition, there was a number of hypersensitivity loci identified in the WT pools that did not pass the discovery criteria in the double mutant (FDR<0.05; $W_{\text{diff}}>0.1$). A number of these below-threshold candidates in the gyrA$^R$ parC$^R$ double mutant strain background encoded subunits of the proteins identified as ciprofloxacin-hypersensitive loci (green circles, Fig. 3C; Data Set S3). These results are similar to what we had observed in our graded series of drug treatments of insertion pools in the WT strain, indicating that the results from the WT strain and the drug resistant double mutant are largely the same.

The results from the gyrA$^R$ single mutant background, however, diverged greatly from the WT and the gyrA$^R$ parC$^R$ double mutant (Fig. 3E). A large fraction of insertions were identified that altered drug sensitivity to ciprofloxacin, with a surprising number showing increased fitness during drug exposure (Fig. 3E). Over 40 of the insertions that exhibited increased fitness were located in putative prophage genes (blue and yellow circles, Fig. 3E; Fig. 3F) from two of the three predicted phages integrated into the bacterial chromosome (Fig. 3B; Data Set S2). No such fitness changes were seen in the WT (Fig. S2, Data Set S1) or gyrA$^R$ parC$^R$ double mutant (Fig. 3C, Data Set S3). To analyze this result further, the normalized fitness of mutations in each gene was plotted as a function of position on the chromosome. In the absence of antibiotic, there was no clear positional effect of altered fitness levels along the length of the chromosome (Fig. 3G). In contrast, in the presence of antibiotic, there was an apparent increase in fitness levels centered within chromosomal locations harboring prophages P1 and P3 in the gyrA$^R$ single mutant (Fig. 3G). Although some of this effect could be explained by loss of prophage gene function resulting in enhanced fitness, insertions in chromosomal regions near, but outside, the prophage boundaries similarly showed apparent increases in fitness relative to the rest of the chromosomal
insertions (Figs. 3G and H). As fitness levels are measured by counting the number of reads in specific regions of DNA, this phenomenon is consistent with selective local amplification of chromosomal material that initiates within these prophages, extending outward from the integration sites into nearby DNA regions.

Two prophage regions are selectively amplified in response to ciprofloxacin in the single gyrAR mutant. We next tested the model that there is induction of DNA synthesis in the region surrounding two of the chromosomally-located prophage clusters. Purified single colonies from the WT, gyrAR, and gyrARparCR double mutant strains were grown in broth culture for 3.5 hours in the presence of four different concentrations of ciprofloxacin that ranged from 30-80% growth inhibition and compared to bacteria grown in the absence of drug (Fig. 4A). DNA was then prepared from each of the cultures and subjected to whole genome sequencing using an average read length of 100 bp. The density of these individual short reads was plotted as a function of the chromosomal coordinates, to identify regions of chromosomal DNA that were selectively amplified in the presence of drug (Fig. 4B). Analysis of the gyrAR single mutant showed hyperamplification of prophages 1 and 3, with read density in the prophage regions observed as a function of drug concentration. In contrast, there was little evidence of this selective amplification in the WT strain, while the gyrARparCR largely reversed these effects. Consistent with the Tn-seq data, there was amplification of DNA extending beyond the prophage-chromosomal DNA junction, indicating that drug-driven DNA synthesis was initiated in situ and continued beyond the ends of the prophages into adjacent chromosomal DNA (Fig. 4C). We conclude that in a gyrAR background, selective blockage of the parC-encoded Topo IV protein resulted in DNA synthesis induction in these two prophage regions.
To determine if transcription of prophage genes is specifically amplified in the $gyrA^R$ mutant relative to the WT, the two strains were grown in triplicate cultures in two concentrations of antibiotic for 3.5 hours that gave between 40-70% growth inhibition over approximately 7 generations (Fig. 5A). The cells were then extracted, subjected to RNAtag-seq analysis (42), and the ratio of transcription for each gene in the presence/absence of ciprofloxacin was displayed as a function of chromosomal map position (Fig. 5B, Data Set S4). There was preferential amplification of transcription of prophage genes in the presence of antibiotic treatment in both strain backgrounds (Fig. 5B). Furthermore, transcription was hyperactivated in all three prophages, including prophage 2 which showed no evidence of preferential DNA amplification (compare Figs 4B and 5B). Higher expression levels were observed with prophage genes in the $gyrA^R$ single mutant compared to WT (Fig. 5B), and these levels were also apparent when directly comparing transcription in WT and $gyrA^R$ after ciprofloxacin treatment (Fig. S3). In $gyrA^R$-single mutants, enhanced expression in response to ciprofloxacin extended beyond the prophage-chromosomal DNA junctions with prophage 1 and to some extent with prophage 3 (Fig. 5C and S3), consistent with increased DNA template availability partially contributing to heightened transcription in this strain background. Hyperexpression in response to ciprofloxacin terminated at the prophage-chromosomal DNA junctions with prophage 2, consistent with the observation that this region experienced no DNA amplification (Fig. 5C). These results indicate that preferential blockage of Topo IV in the single mutant results in hyperactivation of prophage transcripts.

Intoxication of bacterial topoisomerase enzymes by fluoroquinolone antibiotics induces DNA damage, driving an SOS response (16, 43). We investigated the extent to which ciprofloxacin-induced hyperactivation of prophage gene expression coincided with SOS
response induction, and whether gyrA or parC resistance alleles influenced this response. Several genes associated with the SOS response (27, 43, 44) showed heightened transcription as a consequence of ciprofloxacin treatment (Fig. 6A). For several SOS genes, transcript induction was significantly higher in gyrA\(^\text{R}\) compared to WT (Fig. 6A; asterisks). These included genes adjacent to prophage-chromosomal DNA junctions (umuC and umuD paralogs) as well as those not directly linked to prophages (recA, gst; Fig. 6B). RecA is a key component of the SOS response that is induced by DNA damage in A. baumannii and is critical for withstanding ciprofloxacin stress independent of the background resistance genotype (see Data Sets S1-S3).

To analyze the interplay of SOS induction by ciprofloxacin with target availability at the level of single cells, we utilized a plasmid-based transcriptional fusion of the recA regulatory elements (promoter and 5’-untranslated region) to the fluorescent reporter mKate2 (45). WT, gyrA\(^\text{R}\), and gyrA\(^\text{R}\)parC\(^\text{R}\) strains harboring the reporter fusion were cultured in the presence of graded levels of ciprofloxacin, and reporter signal was measured in individual cells by fluorescence microscopy (Materials and Methods). Increasing sub-MIC doses of ciprofloxacin caused increasing degrees of induction of the recA reporter in all strain backgrounds (Fig. 6C). Notably, reporter activity was approximately 2-fold higher in the gyrA\(^\text{R}\) single mutant than in the WT or double mutant at equivalent levels of growth inhibition (Fig. 6C). Varying degrees of recA induction within populations of gyrA\(^\text{R}\) single mutant cells were observed, and this variability roughly matched that observed with WT (Fig. S4). Increased signal in the gyrA\(^\text{R}\) strain was not observed with a control reporter fusion to a gene that is nonresponsive to ciprofloxacin (trpBp-UTR) (45), Fig 6D), indicating that the SOS transcriptional response was specifically enhanced as a consequence of ciprofloxacin inhibition of Topo IV.
Discussion

In this study we exploited the dual-target nature of fluoroquinolone antibiotics to uncover how resistance alleles acquired in target enzymes modulate the landscape of intrinsic resistance. Using Tn-seq, we performed comprehensive screens for determinants of resistance to the fluoroquinolone drug ciprofloxacin in isogeneic *A. baumannii* strains in which the drug preferentially targets either DNA gyrase or Topo IV. We found that the spectrum of genes contributing to intrinsic resistance was similar in genetic backgrounds in which both enzymes were WT or in which both enzymes had lowered drug sensitivity due to well-known acquired point mutations. Intrinsic resistance determinants identified in both backgrounds included the AdeIJK and AbeM efflux pumps, multiple subunits of the DNA recombination and repair machinery, a periplasmic protease CtpA, the cell wall transpeptidase PBP1A, and several proteins of unknown function. By contrast, interaction of ciprofloxacin with the gyrA\(^R\) single mutant in which Topo IV is the sensitive target dramatically altered the profile of genes that influence relative Tn-seq fitness. This altered fitness profile in *gyrA\(^R\)parC\(^+\)* bacteria was shown to directly reflect amplification of DNA in the vicinity of two endogenous prophages due to preferential poisoning of Topo IV by ciprofloxacin. Phage transcripts and the SOS pathway were also hyperactivated as a consequence of this drug-genotype interaction, likely facilitating the initiation of synthesis of prophage DNA in the *gyrA\(^R\)* strain.

Our data can be explained by the model shown in Fig. 7, if we assume that re-activation of *A. baumannii* prophages 1 and 3 requires the function of host DNA gyrase. In WT and the *gyrA\(^R\) parC\(^R\)* double mutant, DNA gyrase is the effective target blocked by ciprofloxacin at growth-inhibitory, sub-MIC drug concentrations. Phage DNA synthesis is blocked despite
induction of the DNA damage response and prophage gene transcription because, as postulated
by the model, efficient replication of the prophage genomes requires functional host gyrase (Fig.
7A and C). By contrast, in gyrA<sup>R</sup> bacteria, Topo IV is the preferred target of intoxication by
ciprofloxacin. This interaction causes DNA lesions that robustly stimulate the SOS pathway and
prophage transcription; further, host DNA gyrase is available to facilitate prophage genome
replication because the GyrA S81L (gyrA<sup>R</sup>) variant is resistant to the intermediate concentrations
of ciprofloxacin required for Topo IV poisoning (Fig. 7B). Therefore, the presence of the single
gyrA<sup>R</sup> resistance generates a liability that is not observed in other strains, resulting from the
induction of potentially lethal prophage replication in the presence of fluoroquinolones.

The central assumption of the model is plausible based on analogy with several other
bacteriophage systems that have been shown to require host DNA gyrase for replication. Gyrase
inhibitors (quinolones or aminocoumarins) inhibit phage DNA replication during lytic growth
after infection (46-51), and disrupt induction of replicative transposition in Mu lysogens (52).
Moreover, host gyrase is required for propagation of replication forks within supercoiled DNA
substrates in reconstituted systems modeling phage lambda replication (53, 54). The importance
of this enzyme class for replication of <i>A. baumannii</i> strain 17978 prophages is emphasized by the
fact that they do not encode type II topoisomerases which are often encoded by bacteriophages to
bypass a requirement for the host enzymes (55, 56).

An alternative model is that at the sub-MIC drug doses resulting in equivalent growth
inhibition, gyrase poisoning results in DNA lesions that do not stimulate the SOS response above
the threshold required for efficient prophage induction, in contrast to lesions caused by Topo IV
poisoning. Arguing against this model are the observations that transcription of the SOS response
gene recA and genes from all three prophages are strongly induced (25-50 fold, Figs. 5B and 6C)
above baseline in WT cells, and Tn-seq fitness results showing the relatively similar importance of DNA damage repair enzymes across all strain backgrounds (Data Sets S1-S3). We showed that Topo IV intoxication stimulated the SOS pathway to a greater extent than that caused by gyrase poisoning, potentially contributing to the robust activation of prophages. This is consistent with previous findings that Topo IV and gyrase intoxication can be distinguished by several characteristics. Topo IV lesions result in slower inhibition of DNA synthesis and are thought to be more readily reversed by recombinational repair, resulting in lower cytotoxicity at given drug concentrations (16). These less toxic lesions could potentially expose more numerous or potent signals for the SOS response that could result in prophage induction.

In contrast with induction of prophages 1 and 3, ciprofloxacin-induced DNA replication was not observed with prophage 2 despite activation of prophage gene transcription. One possible explanation is that prophage 2 is defective for DNA replication. We consider this unlikely because transposon insertions were unobtainable in a phage locus (ACX60_RS10145) encoding a putative Cro/Cl family repressor (Data Sets S1-S3), indicating that this prophage has the potential for lytic replication in the absence of a protein controlling lysogeny maintenance. Consistent with the potential of all three prophages (including prophage 2) for replication, mobilized DNA corresponding to each of the three prophages was detected in phage particles resulting from treatment of WT A. baumannii 17978 with mitomycin C, which damages DNA directly without dependence on interactions with DNA topoisomerases (44). An alternative explanation for the lack of prophage 2 DNA amplification observed with fluoroquinolone treatment in our study is that its replication depends on both DNA gyrase and Topo IV.

The findings described here have implications for the evolution of antibiotic resistance in A. baumannii and other Gram-negative organisms. They indicate that in the trajectory toward
high-level fluoroquinolone resistance, intermediate states with moderate-level fluoroquinolone resistance (exemplified by the \( \text{gyrA}^R \) single mutant) are those that possess highest potential for prophage induction during growth with continued drug exposure. Depending on the outcome of phage-host interactions, prophage hyperamplification within these bacteria could impose a fitness burden or could result in cell death if productive lysis ensues, representing additional selective pressures to influence evolution when under stress from the inducing antibiotic.

Acquiring the subsequent \( \text{parC} \) mutation would answer this pressure and result in high-level fluoroquinolone resistance. It is notable that hyperamplified and hyperexpressed DNA within or adjacent to induced prophages include multiple \( \text{umuCD} \) paralogs encoding mutagenic DNA polymerases (57), whose higher levels of activity could increase mutation frequency and hasten bacterial adaptation in drug-treated \( \text{gyrA}^R \) single mutants. Moreover, these findings raise the possibility of enhanced horizontal transfer of phage-encoded and phage-proximal genes as a consequence of fluoroquinolone-\( \text{gyrA}^R \) interactions. The relationship between stepwise fluoroquinolone resistance and induction of prophages by this drug class may play out differently with Gram-positive organisms in which Topo IV is typically the sensitive initial target as opposed to gyrase (6). If fluoroquinolone-prophage dynamics in such bacteria have features that accord with the model proposed here, WT strains with two sensitive \( \text{parC} \) and \( \text{gyrA} \) alleles may represent the state with higher potential for drug-induced prophage replication than derivatives that have acquired single-step target-resistance mutations.

In summary, we have demonstrated that in the course of stepwise selection for high drug resistance, intermediate steps result in unexpected nodes of hypersensitivity that place both added pressure for acquisition of additional drug resistant alleles, as well as inducing the enzymatic machinery that drives acquisition of drug resistance. Future work on analysis of
proteins that modulate the survival of drug resistant mutants should uncover strategies that allow these variants to be targeted therapeutically.

Materials and Methods

Bacterial strains, growth conditions, and antibiotics. Bacterial strains used in this work are described in Table S1. A. baumannii strains were derivatives of ATCC 17978. Bacterial cultures were grown at 37°C in Lysogeny Broth (LB) (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl) in flasks with shaking or in tubes on a roller drum. Growth was monitored by measuring absorbance at 600nm via a spectrophotometer. LB agar was supplemented with antibiotics [ampicillin (Amp, 50-100 μg/ml), carbenicillin (Cb, 50-100 μg/ml), kanamycin (Km, 10-20 μg/ml), mecillinam, ciprofloxacin] or sucrose as needed (Sigma Aldrich).

Molecular cloning and mutant construction. Oligonucleotide primers and plasmids used in this study are listed in Table S2. Single gyrAS1L (gyrAR) and parCS84L (parCR) point mutations were generated by cloning the respective genomic fragments in pUC18, followed by inverse PCR and self-ligation or amplification and substitution of a mutated gene fragment. In-frame deletions of ciprofloxacin-resistance genes were generated as described (58). Constructs were subcloned in pSR47S and used to isolate A. baumannii mutants via homologous recombination with two selection steps (58). The gyrAR parCR double mutant was isolated by selection of a derivative of the gyrAR strain able to grow on LB agar containing 8 μg/ml ciprofloxacin. A pbpla mutant (N178TfsX27) was isolated as a derivative of ATCC 17978 selected on LB agar containing 64 μg/ml mecillinam.
Antibiotic susceptibility assays. For growth curve analysis, cultures were seeded at $A_{600} = 433$ 0.003 in 100µl of broth in wells of a 96-well microtiter plate and growth monitored during incubation at 37°C with orbital shaking in a Tecan M200 Pro plate reader. MIC tests were performed under the conditions above using serial 2-fold dilutions of drug; the MIC was the lowest drug concentration preventing growth above $A_{600} = 0.05$ after 16 hours.

Construction of transposon mutant libraries. Plasmid pDL1073 was employed for transposon mutagenesis. pDL1073 contains a Km$^R$ Tn10 derivative, an altered target-specificity Tn10 transposase gene downstream of the phage lambda P$_L$ promoter, a pSC101ts origin of replication, and β-lactamase (Amp$^R$; Fig. S1). pDL1073 does not replicate in A. baumannii at 37°C allowing efficient detection at this temperature of transposition after delivery via electroporation. A. baumannii cells (50µl) were combined with 100ng pDL1073 and electroporated via a BioRad Gene Pulser (0.1cm gap length cuvette; 200Ω, 25µF, and 1.8kV). Electroporated cells were diluted with SOC broth and immediately spread onto membrane filters (0.45µm pore size) overlaid on pre-warmed LB agar plates. After incubating 2 hours at 37°C, the filter membranes were transferred to pre-warmed LB agar plates containing 20µg/ml Km and incubated at 37°C overnight to select for transposon mutants. Bacterial colonies were lifted from the filter by agitation in sterile PBS. Glycerol was added to 10% (v/v), and pooled mutant suspensions were aliquoted and stored at -80°C. 11-15 independent pools each consisting of approximately 6,000-18,000 mutants were generated in each strain background.

Tn-seq fitness measurements. Transposon library aliquots were thawed, vortexed, diluted to $A_{600} = 0.1$ and grown to $A_{600} = 0.2$ in LB. Cultures were then back-diluted to $A_{600} = 0.003$ in 100µl of broth in wells of a 96-well microtiter plate and growth monitored during
10ml LB without drug or with graded concentrations of ciprofloxacin. Parallel cultures were
grown at 37˚C for approximately 8 generations to $A_{600} = 0.5-1$. Samples taken at the start ($t_1$) and
end ($t_2$) of this outgrowth were stored at -20ºC. 11 to 15 independent transposon libraries were
analyzed with each strain background. With WT libraries, treatments with 0.075 µg/ml and 0.09-
0.1 µg/ml ciprofloxacin were performed in parallel with the same untreated control.

**Tn-seq Illumina library preparation.** Genomic DNA was extracted from $t_1$ and $t_2$ samples
(Qiagen DNeasy Kit) and quantified by a SYBR green microtiter assay. Transposon-adjacent
DNA was amplified for Illumina sequencing using a modification of the Nextera™ DNA Library
Prep method (Illumina). 30ng of genomic DNA was used as input in a 10µl tagmentation
reaction. Reaction conditions were 55˚C for 5min followed by inactivation at 95˚C for 0.5min.
Transposon-adjacent genomic DNA was amplified by adding 40µl of PCR master mix
containing primers olj928 and Nextera 2A-R (0.6µM final) and Q5 High-Fidelity polymerase
(NEB). Reaction conditions were 98˚C for 10s, 65˚C for 20s, and 72˚C for 1min (30 cycles),
followed by a final extension at 72˚C for 2min. A second PCR was performed using nested,
indexed primers. This reaction contained 0.5µL of the first PCR reaction, Left Tn10 indexing
primer (0.6µM), Right indexing primer (0.6µM) and Q5 polymerase in a 50µl final volume.
Reaction conditions were 98˚C for 10s, 65˚C for 20s, and 72˚C for 1min (12 cycles of), followed
by a final extension at 72˚C for 2min. A sample of the second PCR product was imaged after
separation on a 2% agarose/TAE gel containing SYBR Safe dye. Samples were multiplexed
based on signal intensity in the 250-600bp region and purified (Qiagen QIAquick). 15-20pmol of
DNA was used as template in a 50µl reconditioning reaction containing adapter-specific primers
P1 and P2 (0.6µM) and Q5 polymerase. Reaction conditions were 95˚C for 1min, 0.1˚C/sec ramp
to 64°C, 64°C for 20s, 72°C for 10min. Samples were purified (Qiagen QIAquick), followed by quantification and size selection (250-600bp, Pippin HT) by the Tufts University Genomics Core Facility (TUCF-Genomics). Libraries were sequenced (single-end 50bp) using custom primerolk115 on a HiSeq2500 with High Output V4 chemistry at TUCF-Genomics.

**Tn-seq data analysis.** Reads were demultiplexed, quality-filtered and clipped of adapters before serving as input for mapping and fitness calculations (31). Reads were mapped to the *A. baumannii* 17978-mff chromosome (NZ_CP012004) and plasmids (NC_009083, NC_009084, and NZ_CP012005) using previously described parameters (59). Fitness values for each transposon mutant were calculated by comparing mutant vs population-wide expansion between *t*₁ and *t*₂ (31). Per-gene average fitness and SD were then computed from fitness scores for all insertion mutations within a gene across multiple parallel transposon pools. Differences in average gene fitness between treated and untreated conditions (*W*ₐₐᵢ₉) were considered significant if they fulfilled the following 3 criteria, with minor modification from those previously described (33): per-gene fitness must be calculated from at least 3 data points, the magnitude of *W*ₐₐᵢ₉ must be > 10%, and q value must be < 0.05 in an unpaired t-test with FDR controlled by the 2-stage step-up method of Benjamini, Krieger and Yekutieli (GraphPad Prism 7). Per-insertion fitness scores within a given genomic region were visualized using Integrative Genomics Viewer software (60) after aggregating all scores across multiple independent transposon mutant libraries using the SingleFitness Perl script (61).

**Whole-genome sequencing of individual strains subjected to ciprofloxacin.** WT, gyrA<sup>R</sup>, or gyrA<sup>R</sup> parC<sup>R</sup> strains were grown from single colonies to early post-exponential phase and back-
diluted to $A_{600} 0.003$. Parallel cultures were grown for 2.5 hours in the absence of treatment, or 3.5 hours in the presence of ciprofloxacin treatment. DNA was extracted (Qiagen DNeasy) and Illumina sequencing libraries were amplified and sequenced as described (34). After mapping to NZ_CP012004, coverage files were generated from the resulting BAM files using deepTools, with reads normalized to counts per million (62).

**Transcriptional profiling.** Cultures were diluted to $A_{600} 0.003$ and grown for 2.5 hours (untreated) or 3.5 hours (ciprofloxacin treated). Cultures were mixed with an equal volume of ice-cold acetone:ethanol (1:1) and stored at -80°C. Cells were thawed and washed with TE and RNA was extracted (Qiagen RNeasy). RNA samples were diluted, combined with SUPERase-in (Invitrogen), and processed via the RNAtag-seq method (42). Illumina cDNA sequencing libraries were sequenced and reads processed as described (63). Differential expression was calculated using DESeq2 (64).

**Fluorescence reporter assays.** Strains containing pCC1 or pCC7 were cultured in the presence or absence of ciprofloxacin as in RNA-seq experiments. Cells were immobilized on agarose pads and imaged on a Leica AF6000 microscope using a 100X/1.3 objective and TX2 filtercube (excitation: BP 560/40, dichromatic mirror 595, emission: BP 645/75). MicrobeJ (65) was used to measure background-corrected mean fluorescence intensity per cell. Median cellular fluorescence intensities from populations of at least 100 bacteria were determined, and median values across multiple independent experiments were averaged.
Accession Number(s). Sequencing reads analyzed in this study were deposited into SRA database as: SRP157243 (Tn-seq), PRJNA495614 (RNA-seq), and PRJNA495623 (Whole genome sequencing).

Acknowledgements.

This work was supported by NIAID awards U01AI124302 to RRI and TVO, R21AI128328 to RRI, and F32AI098358 to EG. NSF REU Site Award #1757443 to the Northeastern University Department of Biology supported the research of ELW. We thank Carly Ching and Veronica Godoy for gift of pCC1 and pCC7, and Amy Tang for assistance with bioinformatics analysis.

References


mutations promote the evolution of antibiotic resistance in a multidrug environment. Elife 6.


Figure Legends.

Fig. 1. Tn-seq quantification of genome-wide mutant fitness in A. baumannii (gyrA\textsuperscript{WT} and parC\textsuperscript{WT}) during growth with sub-MIC ciprofloxacin. (A) Graded concentrations of ciprofloxacin cause increasing degrees of growth inhibition. Transposon mutant libraries constructed in a strain background harboring WT alleles of the gyrA and parC genes were grown...
with ciprofloxacin at the concentrations indicated. Growth rate relative to untreated control was
determined from bacterial density measurements. Data points show average ± SD (n ≥ 2). (B)
Tn-seq fitness profiles during ciprofloxacin challenge. Mutant pools were grown with or without
the indicated ciprofloxacin concentration and average fitness for each chromosomal gene was
calculated. Change in fitness resulting from ciprofloxacin treatment relative to untreated controls
is plotted against significance score resulting from parallel t-tests. Data points shaded in black
indicate gene knockouts causing significant alteration in fitness during drug challenge (W_{treated}-
W_{untreated} had a magnitude > 0.1 and FDR <0.05). (C) Functional categories of significant gene
hits determining fitness during challenge with 0.09-0.1 µg/ml ciprofloxacin. Information from
KEGG and UniProt functional annotations and from orthologs in well-studied reference species
were used to place genes into the listed broad categories.

Fig. 2. Magnitude of growth impairment is predicted by the severity of the Tn-seq fitness
defect. (A) Tn-seq fitness profiles of transposon mutant pools constructed in a gyrA^{WT} parC^{WT}
strain. Pools were grown without or with ciprofloxacin at 0.09-0.1 µg/ml. Bars show fitness
values of each transposon mutant at the indicated locus across all tested pools. (B) Growth of
pure cultures of WT or the indicated mutant in the absence or presence of ciprofloxacin (0.09
µg/ml for ΔctpA and pbp1A, 0.1 µg/ml for ΔadeIJK and ΔrecN, and 0.15 µg/ml for ΔgidA). The
pbp1a mutant tested was pbp1a(N178TfsX27). Data points show geometric mean ± SD (n = 3).
Cip, ciprofloxacin.

Fig. 3. Acquisition of gyrA resistance allele dramatically alters A. baumannii Tn-seq profile
during ciprofloxacin challenge. (A) Transposon pools constructed in strains harboring
resistance alleles in gyrA or both gyrA and parC require increasing concentrations of ciprofloxacin to result in growth inhibition. Growth rate inhibition relative to untreated pools was plotted as in Fig. 1A. gyrA<sup>WT</sup> parC<sup>WT</sup> growth data are from identical experiment shown in Fig. 1A and are displayed to allow comparison to behavior of drug resistant mutants. Data points show average ± SD (n ≥ 2). Samples from cultures with 30-40% growth inhibition (dotted lines) were processed for Tn-seq. (B) Location of prophage regions (P1-P3) on A. baumannii 17978-mff chromosome map. Prophage positions were identified by using the PHASTER database (66). (C-F) gyrA resistance allele influences Tn-seq fitness profiles associated with ciprofloxacin stress. Mutant pools were challenged with drug concentrations that resulted in equivalent 30-40% growth inhibition [gyrA<sup>R</sup>, 1.1 µg/ml; gyrA<sup>R</sup> parC<sup>R</sup>, 13-14 µg/ml]. (C, E) Tn-seq fitness scores for each chromosomal gene with the indicated strain were calculated and visualized as in Fig. 1B (leftmost subpanel). Middle and rightmost subpanels show the identical dataset, with highlighting of loci for which knockout causes ciprofloxacin hypersensitization in the WT genetic background (green), or loci within prophages (color indicated in key). (D, F) Gene hits associated with significant changes in fitness during treatment were placed into functional categories as in Fig. 1C. Tn-seq hits resulting from gyrA<sup>R</sup> libraries treated with ciprofloxacin are enriched in prophage genes (F). (G) Tn-seq fitness scores resulting from ciprofloxacin challenge show genome positional bias that is greatly amplified in gyrA<sup>R</sup> mutant pools. Average per-gene Tn-seq fitness values are plotted in order of gene position on the chromosome or on plasmids pAB1-3. Boundaries of prophage regions (P1-P3) are indicated by vertical dotted lines. Top, no drug control. Bottom, ciprofloxacin was added at the concentrations indicated in panel A resulting in 30-40% inhibition (WT, 0.09-0.1 µg/ml; gyrA<sup>R</sup>, 1.1 µg/ml; gyrA<sup>R</sup> parC<sup>R</sup>, 13-14
μg/ml). (H) Expanded view of per-gene Tn-seq fitness scores in regions surrounding prophages P1 and P3 for gyrA<sup>R</sup> mutant treated with 1.1 μg/ml ciprofloxacin.

Fig. 4. Ciprofloxacin-induced amplification of prophage DNA in strains harboring the gyrA<sup>R</sup> single-step resistance genotype. (A) Pure cultures of strains of the indicated genotype were challenged with graded ciprofloxacin doses resulting in four levels of growth inhibition (Roman numerals). (B) DNA content from each culture was analyzed by deep sequencing. x-axis indicates nucleotide position along the A. baumannii ATCC17978-mff chromosome. y-axis indicates normalized read depth (0-140 counts per million). Boundaries of prophage regions P1-3 are indicated in red. Roman numerals indicate the level of growth inhibition caused by ciprofloxacin. Data are representative of two independent experiments. (C) Expanded view of 300kb window showing amplification of genomic regions surrounding prophages P1 and P3. Y-axis indicates normalized sequencing read depth (0-160 counts per million).

Fig. 5. Ciprofloxacin challenge results in activation of prophage gene expression that is heightened in gyrA<sup>R</sup>-single mutants. (A) Strains of the indicated genotype were challenged with ciprofloxacin concentrations that resulted in two levels of growth inhibition relative to no treatment (i, ~45% growth inhibition; ii, ~70% growth inhibition). Data points show average ± SD (n = 3). (B). RNA-seq transcriptional profiles of panel A cultures. Fold change (log2) of each gene (treated vs untreated) was plotted in order of position on the chromosome or plasmids (pAB1-3). rRNA and tRNA genes were excluded from RNA-seq analysis, resulting in different gene number assignments as compared to those in Fig. 3D. Boundaries of prophage regions P1-3 are denoted by vertical dotted lines. Roman numerals indicate growth inhibition level. (C)
Expanded views of RNA-seq log2-fold change ratios for genes surrounding P1-3 in gyrA<sup>R</sup>-single mutant (condition ii, ciprofloxacin 1.1µg/ml).

Fig. 6. Enhanced SOS response induction in gyrA<sup>R</sup>-single mutants exposed to ciprofloxacin. (A-B) SOS response genes are induced during growth with ciprofloxacin. (A) RNA-seq data reveal DNA damage/SOS response induction during growth with ciprofloxacin. Bars show log2 fold change ± SEM (n = 3) for WT or gyrA<sup>R</sup>-single mutant treated with ciprofloxacin concentrations resulting in ~70% growth inhibition (condition ii from Fig. 5). *, p<0.05, unpaired t test. (B) Location of DNA damage/SOS response genes induced in gyrA<sup>R</sup>-single mutant strain. x-axis indicates gene position along the A. baumannii chromosome, y-axis indicates the log2 fold change (Cip 1.1µg/ml vs untreated, gyrA<sup>R</sup>-single mutant) from previously presented RNA-seq data. (C-D) Fluorescence reporter assays demonstrate enhanced recA gene expression in gyrA<sup>R</sup>-single mutant. Strains of the indicated genotype harboring (C) pCC1 (mKate2 fusion to recA promoter plus 5’ untranslated region (UTR)) or (D) pCC7 (trpB promoter replacing recA promoter in pCC1) were cultured as in RNA-seq experiments. Growth inhibition relative to untreated control was calculated (top). Average mKate2 intensity per cell within each sample was measured by fluorescence microscopy, and median fluorescence values of the population were determined (bottom). Data points represent the average inhibition values (top) or average of median fluorescence values (bottom) ± SD from n ≥ 2 biological replicates pooled from multiple independent experiments. Dotted lines denote fluorescence intensity of untreated samples.
Fig. 7. Model for resistance allele-dependent prophage amplification in *A. baumannii*

exposed to sub-MIC fluoroquinolone stress. The model posits that prophage DNA replication
depends on host DNA gyrase activity. (A) In WT cells, both gyrase (GyrA) and topo IV (ParC)
are drug sensitive. Gyrase, which has higher affinity for CIP (blue triangles), is effectively
targeted by the drug. Ciprofloxacin-corrupted gyrase results in double-strand DNA breaks that
signal derepression of prophage gene expression. Prophage DNA replication cannot proceed,
however, because gyrase function is blocked. (B) In single *gyrA*<sup>R</sup> mutant cells, topo IV/ParC has
higher affinity for ciprofloxacin than the resistant gyrase and is the effective drug target. Topo IV
corruption results in a robust DNA damage response and activation of prophage gene expression,
and gyrase-dependent prophage replication (prophages 1 and 3) proceeds because GyrA is not
drug-inhibited. (C) In double *gyrA*<sup>R</sup>*parC*<sup>R</sup> mutant cells growing at high drug concentrations,
GyrA again has relatively higher affinity for ciprofloxacin than ParC and becomes the effective
target despite the S81L drug binding site alteration. The resulting DNA lesions induce the SOS
response and prophage gene expression, but prophage replication does not proceed efficiently
because gyrase function is again blocked.

Supplemental Figure Legends

Fig. S1. pDL1073 feature map.

Fig. S2. Sub-MIC ciprofloxacin treatment of *A. baumannii* with *gyrA*<sup>WT</sup> and *parC*<sup>WT</sup> alleles
does not significantly alter Tn-seq fitness values assigned to prophage region genes. (A) The
Tn-seq dataset shown in Fig. 1B (WT background +/- treatment with ciprofloxacin 0.09-0.1
μg/ml) was reanalyzed to highlight fitness values associated with genes within prophage regions P1-P3. Prophages regions are highlighted with color indicated in the key.

**Fig. S3. Comparison of transcription levels between ciprofloxacin-treated cultures of WT and gyrA<sup>R</sup> reveals enhanced prophage gene expression in the gyrA<sup>R</sup> single mutant.** Strains were grown in the absence or presence of ciprofloxacin at concentrations shown in Fig. 5A, and RNA-seq data were analyzed such that WT and gyrA<sup>R</sup> strains were directly compared at each condition. Plots show log2 fold change (WT vs gyrA<sup>R</sup>) of each gene in order of position on the chromosome or plasmids (pAB1-3).

**Fig. S4. Fluorescence microscopy analysis of SOS response in individual cells subjected to ciprofloxacin.** Strains harboring recA-mKate2 were cultured and analyzed by fluorescence microscopy as described in legend to Fig. 6C. (A) Phase contrast (rows 1 and 3) and fluorescence (rows 2 and 4) microscopy images from one representative experiment used to quantify recA-mKate2 signal in Fig. 6C. Cells of the indicated genotype were treated with the noted concentration of ciprofloxacin resulting in similar degrees of growth inhibition (see panel C, bottom three growth inhibition data points). (B) Population fluorescence analysis from one representative experiment contributing to Fig. 6C quantifying SOS response to increasing ciprofloxacin dose in different strain backgrounds harboring recA-mKate2. In the same experiment shown in panel A, 4 different ciprofloxacin concentrations were tested per strain. Average mKate2 intensity per cell was measured by fluorescence microscopy. Each data point represents average fluorescence intensity of a single cell (at least 100 cells per condition were
analyzed). Bars indicate median values. (C) Growth inhibition relative to untreated control resulting from the ciprofloxacin exposures in the representative experiment shown in panel B.

Table S1. Bacterial strains and plasmids used in this study.

Table S2. Oligonucleotide primers used in this study.

Data Set S1. Tn-seq fitness data - WT.

Data Set S2. Tn-seq fitness data - gyrA<sup>R</sup>.

Data Set S3. Tn-seq fitness data - gyrA<sup>R</sup> parC<sup>R</sup>.

Data Set S4. RNA-seq data.
Table 1. Minimal Inhibitory Concentration (µg/ml) of Ciprofloxacin with WT and mutant A. baumannii.

<table>
<thead>
<tr>
<th>strain</th>
<th>GyrA</th>
<th>ParC</th>
<th>ciprofloxacin MIC (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>-</td>
<td>-</td>
<td>0.25</td>
</tr>
<tr>
<td>gyrA&lt;sup&gt;R&lt;/sup&gt;</td>
<td>S81L</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>parC&lt;sup&gt;R&lt;/sup&gt;</td>
<td>-</td>
<td>S84L</td>
<td>0.25</td>
</tr>
<tr>
<td>gyrA&lt;sup&gt;R&lt;/sup&gt; parC&lt;sup&gt;R&lt;/sup&gt;</td>
<td>S81L</td>
<td>S84L</td>
<td>32</td>
</tr>
</tbody>
</table>
A

Growth rate (% of untreated) vs. Ciprofloxacin (µg/ml)

WT

gyrA<sup>R</sup>

gyrA<sup>R</sup>parC<sup>R</sup>

B

WT

gyrA<sup>R</sup>

gyrA<sup>R</sup>parC<sup>R</sup>

no drug

+ Ciprofloxacin

C

P1

P3

Chromosome coordinate

Read depth
Strain: 

A: WT 

B: gyrA^R 

C: gyrA^RparC^R 

[Cip] required for growth inhibition: 

Enzyme inhibited by Cip: 

Gyrase > Topo IV 

Topo IV > Gyrase 

Gyrase > Topo IV 

DNA damage response 

Prophage gene transcription 

Prophage DNA replication 

DNA damage response 

Prophage gene transcription 

Prophage DNA replication 

DNA damage response 

Prophage gene transcription 

Prophage DNA replication